Vizient Quality and Accountability Ranking. Ranked #1 out of 115 participating comprehensive academic medical centers." ...

Corbus Pharmaceuticals presented Phase 1 data on CRB-701 at ASCO GU, showing safety, tolerability, and responses across multiple tumor types.

Moderna is now expecting 2025 research and development costs of about $4.1 billion and selling, general and administrative costs of about $1.1 billion. Cost of sales is expected to come to about $1.2 ...

Two months after Allogene abandoned plans for its CAR-T in leukemia, analysts have suggested that fresh phase 1 data in ...

Patients Achieved Remission Within 30 Days in Cohort 1 of the Mipletamig RAINIER Dose Optimization Trial for Frontline AML Patients, Trial Enrollment Continues Promising Data, including a 59% Stable ...

PhaseV, a pioneer in software and machine learning (ML) for advanced clinical development optimization, announced today the launch of its new webinar series exploring the latest innovations in ...

The funding will be used to complete the Phase II/III trial of ulviprubart, and to support commercial launch preparation.

Valuation discrepancies in the biotech sector highlight Shuttle Pharma’s incredible potential. With several peer companies in ...

We think the strategy to find more effective combination therapies in hematology and build a larger oncology and dermatology portfolio is solid, although we're waiting for key data before assuming the ...